Vingraf contains tacrolimus, a potent immunosuppressive medication primarily used to prevent organ rejection in patients who have undergone organ transplants. Tacrolimus helps the body accept a new organ, such as a kidney, liver, or heart, by weakening the immune system’s natural response to foreign tissues. It is also sometimes used in certain autoimmune conditions under specialist supervision.

Mechanism of Action
Tacrolimus works by targeting and inhibiting a protein called calcineurin. This inhibition prevents the activation of T-lymphocytes, which are a critical part of the immune system’s response to what it perceives as foreign bodies, such as a transplanted organ.

By suppressing T-cell activation and the release of inflammatory cytokines, tacrolimus reduces immune attack on transplanted organs, helping them survive longer in the recipient’s body. This action makes it highly effective as a long-term immunosuppressive agent

Uses
Vingraf is prescribed in the following situations:

• Prevention of organ rejection after kidney, liver, or heart transplantation

• Treatment of organ rejection in patients not responding to standard therapies

• Autoimmune diseases, such as severe eczema or lupus nephritis, in selected cases (off-label)

  Adverse Effects
  Though highly effective, tacrolimus requires close monitoring due to its narrow therapeutic range and potential side effects.

  Common side effects include:

  • Tremors

  • Headache

  • Nausea

  • Diarrhea

  • Increased blood sugar levels

  • High blood pressure

  • Insomnia

    Serious or long-term side effects may include:

    • Kidney dysfunction or elevated creatinine levels

    • Increased risk of infections due to immune suppression

    • Increased risk of certain cancers, especially skin cancers and lymphomas

    • Electrolyte imbalances such as low magnesium or high potassium

    • Neurotoxicity, presenting as seizures or confusion in rare cases